Egetis Therapeutics AB (publ)
STO:EGTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Egetis Therapeutics AB (publ)
STO:EGTX
|
SE |
|
K
|
KGHM Polska Miedz SA
OTC:KGHPF
|
PL |
|
Willamette Valley Vineyards Inc
NASDAQ:WVVI
|
US |
|
Derluks Yatirim Holding AS
IST:DERHL.E
|
TR |
|
T
|
Talant Optronics suzhou Co Ltd
SZSE:301045
|
CN |
|
A
|
Asiamet Resources Ltd
OTC:KMGLF
|
CA |
|
City Union Bank Ltd
BSE:532210
|
IN |
|
J
|
JBDI Holdings Ltd
NASDAQ:JBDI
|
SG |
|
Kyung Dong Navien Co Ltd
KRX:009450
|
KR |
Wall Street
Price Targets
EGTX Price Targets Summary
Egetis Therapeutics AB (publ)
According to Wall Street analysts, the average 1-year price target for
EGTX
is 13.67 SEK
with a low forecast of 10.1 SEK and a high forecast of 17.85 SEK.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is EGTX's stock price target?
Price Target
13.67
SEK
According to Wall Street analysts, the average 1-year price target for
EGTX
is 13.67 SEK
with a low forecast of 10.1 SEK and a high forecast of 17.85 SEK.
What is Egetis Therapeutics AB (publ)'s Revenue forecast?
Projected CAGR
180%
The
compound annual growth rate
of Egetis Therapeutics AB (publ)'s revenue for the next 3 years is
180%.
